Assessment of Myocardial Viability Using Multidetector Computed Tomography
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To perform a comprehensive evaluation of multidetector CT myocardial enhancement patterns in patients with an acute ST elevation MI. In particular we plan to assess the relationship between regions with early hypoperfusion and/or late hyperenhancement, and myocardial viability.
| Condition | Intervention |
|---|---|
|
Myocardial Infarction |
Procedure: CT |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Single Blind Primary Purpose: Diagnostic |
| Official Title: | Non-Invasive Assessment of Myocardial Viability Using Multidetector Computed Tomography Post Acute Myocardial Infarction |
- Prediction of viability from myocardial enhancement patterns
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2006 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
20 patients admitted to ICCU with ST elevation MI, and treated with primary angioplasty on admission, will undergo between day 2 and 7 post-MI the following exams: a) multidetector CT: regular scan plus late scan at 10 minutes, to evaluate coronary arteries, regional function and myocardial enhancement, b) echocardiography with echo-contrast to evaluate function and size of abnormally contracting region and remodeling, c) nuclear studies: rest early and late Thallium SPECT, to evaluate perfusion and viability. At 3 months a second echo will be performed to assess recovery of abnormal segments. The perfusion defects on MSCT will be compared with the other modalities and at 3 months will be used to evaluate recovery of myocardial function i.e. viability. Parameters that will be evaluated include opacity of hypoenhanced segments, ratio of normal to abnormal segments, change in opacity between early and late scans, size and transmurality of hypoenhanced segments, and their relation to regional contraction.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- acute ST elevation myocardial infarction
- after primary angioplasty
Exclusion Criteria:
- iodine allergy
- renal failure
- old MI
- arrhythmia
- inability to perform 20 second breath-hold
Contacts and Locations| Israel | |
| Rambam Medical Center | |
| Haifa, Israel, 31096 | |
| Principal Investigator: | Jonathan Lessick, MD DSc | Rambam Health Care Campus |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00285064 History of Changes |
| Other Study ID Numbers: | ram1099_CTIL |
| Study First Received: | January 30, 2006 |
| Last Updated: | October 11, 2008 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Rambam Health Care Campus:
|
MDCT viability |
Additional relevant MeSH terms:
|
Infarction Myocardial Infarction Ischemia Pathologic Processes Necrosis |
Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013